# Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants

> **NCT04371380** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 15 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Cabotegravir Tablets
- **DRUG:** Rilpivirine Tablets
- **DRUG:** Cabotegravir extended release suspension for injection (long-acting)
- **DRUG:** Rilpivirine extended release suspension for injection (long-acting)

## Key facts

- **NCT ID:** NCT04371380
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-16
- **Primary completion:** 2021-12-26
- **Final completion:** 2021-12-26
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-04-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04371380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04371380, "Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04371380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*